All the news Showing 6 of 56 articles from: Genotype 1bGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Daclatasvir + sofosbuvir offers hepatitis C rescue therapy after current standard of care Liz Highleyman / 29 April 2013 An interferon-free regimen of daclatasvir plus sofosbuvir, with or without ribavirin, cured all previously treated hepatitis C (HCV) patients who did not respond to interferon-based triple therapy using the approved HCV protease inhibitors ... AbbVie interferon-free combination cures over 90% of hepatitis C genotype 1 Keith Alcorn / 26 April 2013 A four-drug combination of direct acting antivirals developed by AbbVie cured hepatitis C infection in over 90% of participants in the AVIATOR study, without the need for the use of interferon, researchers reported ... Telaprevir and VX-222 pair well in interferon-free regimen, VX-135 on the horizon Liz Highleyman / 03 December 2012 An all-oral regimen of telaprevir, VX-222 and ribavirin for 12 weeks was generally well-tolerated and produced sustained virological response in approximately 70% of previously untreated chronic hepatitis C patients, according to findings from ... Sofosbuvir and daclatasvir dual regimen cures most people with HCV genotypes 1, 2, or 3 Liz Highleyman / 21 November 2012 A 12-week, once-daily regimen of the hepatitis C (HCV) polymerase inhibitor sofosbuvir and the NS5A inhibitor daclatasvir, without interferon or ribavirin, produced sustained virological response rates for treatment-naive people in the 90 to 100% range, ... Simeprevir is safe and effective with interferon/ribavirin for hepatitis C patients with cirrhosis Liz Highleyman / 19 November 2012 The hepatitis C protease inhibitor simeprevir (formerly TMC435) was generally safe and well tolerated in people with advanced liver fibrosis or cirrhosis and improved sustained response rates when added to pegylated interferon and ... Boceprevir response and resistance differs according to HCV genotype 1 subtype Liz Highleyman / 28 July 2011 People with hepatitis C virus (HCV) genotype 1b respond better to boceprevir and are less likely to develop drug resistance than those with genotype 1a, according to study findings reported ... ← Prev1...23456Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive